文献速递头颈与中枢神经肿瘤

局部晚期头颈癌放化疗的头对头网络荟萃分析

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
PubMed 文献 · Lancet Oncol · 2021-04-13

主要终点总生存显示,超分割放疗联合同期化疗(HFCRT)总生存排名最佳(P score 97%),相比局部区域治疗HR 0·63(95%CI 0·51-0·77),相比含铂同期放化疗(CLRTP)HR 0·82(95%CI 0·66-1·01)。

要点

  • HFCRT总生存优于局部区域治疗,HR 0·63(95%CI 0·51-0·77)。
  • HFCRT对比CLRTP的OS HR 0·82(95%CI 0·66-1·01)。
  • 诱导TaxPF后局部治疗P score 89%,优于CLRTP排名但HR未显著更优。

核心结论

  • HFCRT在局部晚期头颈鳞癌总生存上排名最佳(P score 97%)。
  • 进一步强化放化疗(HFCRT或ICTaxPF-CLRT)可能优于常规放化疗。

研究设计与样本

  • 基于MACH-NC与MARCH个体患者数据的频率学派网络荟萃分析。
  • 纳入1980年1月1日至2016年12月31日入组的非转移性头颈鳞癌随机对照试验。
  • 采用两步随机效应法,以log-rank检验按试验分层比较,局部区域治疗为参照。
  • 主要终点为总生存,采用全局Cochran Q评估同质性与一致性,P score排序治疗。

主要发现

  • 中位随访6·6年(IQR 5·0-9·4)。
  • HFCRT对比局部区域治疗OS的HR 0·63(95%CI 0·51-0·77),P score 97%。
  • HFCRT对比CLRTP的OS HR 0·82(95%CI 0·66-1·01)。
  • CLRTP的P score为78%。
  • ICTaxPF-LRT、加速放疗联合同期化疗、ICTaxPF后CLRT的P score分别为89%、82%、80%,但对比CLRTP的OS HR未显著更优。

临床怎么用

  • 对局部晚期头颈鳞癌,可考虑HFCRT或ICTaxPF-CLRT以进一步强化治疗。
  • HFCRT对比CLRTP的OS HR 0·82(95%CI 0·66-1·01),需结合患者情况个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other. METHODS: We did a frequentist network meta-analysis based on individual patient data of meta-analyses evaluating the role of chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC]) and of altered fractionation radiotherapy (Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck [MARCH]). Randomised, controlled trials that enrolled patients with non-metastatic head and neck squamous cell cancer between Jan 1, 1980, and Dec 31, 2016, were included. We used a two-step random-effects approach, and the log-rank test, stratified by trial to compare treatments, with locoregional therapy as the reference. Overall survival was the primary endpoint. The global Cochran Q statistic was used to assess homogeneity and consistency and P score to rank treatments (higher scores indicate more effective therapies). FINDINGS: 115 randomised, controlled trials, which enrolled patients between Jan 1, 1980, and April 30, 2012, yielded 154 comparisons (28 978 patients with 19 253 deaths and 20 579 progression events). Treatments were grouped into 16 modalities, for which 35 types of direct comparisons were available. Median follow-up based on all trials was 6·6 years (IQR 5·0-9·4). Hyperfractionated radiotherapy with concomitant chemotherapy (HFCRT) was ranked as the best treatment for overall survival (P score 97%; hazard ratio 0·63 [95% CI 0·51-0·77] compared with locoregional therapy). The hazard ratio of HFCRT compared with locoregional therapy with concomitant chemoradiotherapy with platinum-based chemotherapy (CLRTP) was 0·82 (95% CI 0·66-1·01) for overall survival. The superiority of HFCRT was robust to sensitivity analyses. Three other modalities of treatment had a better P score, but not a significantly better HR, for overall survival than CLRTP (P score 78%): induction chemotherapy with taxane, cisplatin, and fluorouracil followed by locoregional therapy (ICTaxPF-LRT; 89%), accelerated radiotherapy with concomitant chemotherapy (82%), and ICTaxPF followed by CLRT (80%). INTERPRETATION: The results of this network meta-analysis suggest that further intensifying chemoradiotherapy, using HFCRT or ICTaxPF-CLRT, could improve outcomes over chemoradiotherapy for the treatment of locally advanced head and neck cancer. FUNDINGS: French Institut National du Cancer, French Ligue Nationale Contre le Cancer, and Fondation ARC.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Petit C, Lacas B, Pignon JP, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021. PMID: 33862002. doi:10.1016/S1470-2045(21)00076-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。